Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study)

by J. Van Wyk, F. Ajana, F. Bisshop, S. De Wit, Y. Osiyemi, J. Portilla, J. Routy, C. Wyen, M. Ait-Khaled, M. Nascimento, K. Pappa, R. Wang, J. Wright, A. Tenorio, B. Wynne, M. Aboud, M. Gartland, K. Smith, Y. El-Bahy
Published 2020-02-01

Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study.

by D Raben, A Mocroft, M Rayment, V M Mitsura, V Hadziosmanovic, Z M Sthoeger, A Palfreeman, S Morris, G Kutsyna, A Vassilenko, J Minton, C Necsoi, V P Estrada, A Grzeszczuk, V Svedhem Johansson, J Begovac, E L C Ong, A Cabié, F Ajana, B M Celesia, F Maltez, M Kitchen, L Comi, U B Dragsted, N Clumeck, J Gatell, B Gazzard, A d'Arminio Monforte, J Rockstroh, Y Yazdanpanah, K Champenois, M L Jakobsen, A Sullivan, J D Lundgren, HIDES Audit Study Group
Published 2015-01-01